Invado Completes NeutraSal® Pilot Study in the Medication-Induced Xerostomia

Share Article

Invado Pharmaceuticals announced the completion of a pilot study for NeutraSal® (supersaturated calcium phosphate rinse) in patients experiencing medication-induced xerostomia or dry mouth. NeutraSal® relieved the symptoms of xerostomia in all subjects while also normalizing the pH of the mouth.

Invado Pharmaceuticals announced the completion of a pilot study for NeutraSal® (supersaturated calcium phosphate rinse) in patients experiencing medication-induced xerostomia or dry mouth. In the study, submitted for publication, NeutraSal® relieved the symptoms of xerostomia in 100% percent of the subjects while also normalizing the pH of the mouth. Patients were evaluated at baseline and throughout the study for their global assessment of dryness as well as their subjective assessment of the specific symptoms of dry mouth. No adverse effects were reported.

“Every patient who tried the product found it to be very successful in relieving their symptoms, and most patients started to incorporate the medicine into their daily routines” stated principal investigator John A. Fritz, MD of Hudson County Primary Care, Jersey City, NJ.

Studies have shown that xerostomia affects approximately 10-29% of the population and more than 400 medications are known to cause xerostomia. The elderly are especially at risk due to taking multiple medications.

About NeutraSal®

NeutraSal® (supersaturated calcium phosphate rinse) is an oral rinse approved for marketing by the FDA under a 510k approval. NeutraSal® is indicated for the dryness of the mouth (hyposalivation, xerostomia); NeutraSal® is also indicated for dryness of the oral mucosa due to drugs such as antihistamines or atropine or other anticholinergic agents that suppress salivary secretion; NeutraSal® may be used as part of an oral hygiene program for patients with dry mouth. NeutraSal® also provides intensive hygiene of the oral cavity. NeutraSal® is also indicated as an adjunct to standard oral care in relieving the discomfort associated with oral mucositis that may be caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with amelioration of pain. NeutraSal® may be used for relief of dryness of the oral mucosa when hyposalivation results from the following: surgery, radiotherapy near the salivary glands, chemotherapy, infection or dysfunction of the salivary glands; fever; emotional factors such as fear or anxiety; obstruction of the salivary ducts; Sjögren’s syndrome
For information, please go to http://www.neutrasal.com.

About Invado Pharmaceuticals
Invado Pharmaceuticals, LLC is a private held pharmaceutical/device company headquartered in Pomona, NY.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Edward Kobus
Invado Pharmaceuticals
(866) 963-8881
Email >
Visit website